Brief: Zhaoke Ophthalmology Says Phase III Trial Of Cyclosporine A Ophthalmic Gel Met Primary Endpoint
Aug 17 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK :
* PHASE III CLINICAL TRIAL OF CYCLOSPORINE A OPHTHALMIC GEL
FOR
TREATMENT OF DRY EYE DISEASE MET ITS PRIMARY ENDPOINT
* CONTINUES TO TARGET SUBMISSION OF A NDA TO NMPA BY END OF
2021
Further company coverage: 6622.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital